⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

July 1, 2026Journal of Thoracic OncologyOpen Access

Brief Report: Reducing Lorlatinib-Related Adverse Events by Establishing the Optimal Exposure-Toxicity Threshold in Patients With NSCLC

D. Lanser Lisanne N. van Merendonk G. D. Marijn Veerman Salomé van Beusekom Esther Oomen-de Hoop Peter De Bruijn Attila Icli Marthe S Paats Alwin D. R. Huitema Ron H.N. van Schaik Sushil Badrising Anne‐Marie C. Dingemans Ron H.J. Mathijssen

View Full Paper

Ask AI

Bookmark

Share

Abstract

above the toxicity threshold, representing approximately one-third of patients, might prevent severe toxicity and improve treatment tolerability.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lanser et al. (2026) studied this question.

synapsesocial.com/papers/6ab087fb4b0be1a99e3f2e7f https://doi.org/10.1016/j.jtho.2026.104093

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN studyLate-Phase Clinical Trial · 2026 · 15 citations
2Lorlatinib Exposure‐Response Analyses for Safety and Efficacy in a Phase I/II Trial to Support Benefit–Risk Assessment in Non‐Small Cell Lung CancerRisk Assessment · 2021 · 29 citations
3Kinetics and management of adverse events associated with lorlatinib after 5 years of follow-up in the CROWN studyCohort Study · 2025 · 8 citations
4Therapeutic Drug Monitoring of Oral Targeted Anticancer Drugs: Achievements, Experiences, Challenges, and the Path Forward2025 · 4 citations
5Lorlatinib in Tyrosine Kinase Inhibitor-Naive Advanced ROS1-Positive Non-Small Cell Lung Cancer: A Phase 2 Nonrandomized Clinical Trial.2025

More from Journal of Thoracic Oncology

P2.335: Use of Renin-Angiotensin System Inhibitors and Risk of CancerThu,
P3.050: Sex Differences in Cardiovascular Outcomes Among Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors: A Real-World AnalysisThu,
The Evolution of Immunotherapy Revolution in Lung Cancer: A 20-Year PerspectiveTue,
Artificial Intelligence in Scientific Writing – Our Editorial PositionSat,
AdvanTIG-302: Phase 3 Study of Ociperlimab (Anti-TIGIT) Plus Tislelizumab (Anti–PD-1) Versus Pembrolizumab in Untreated, Locally Advanced, Unresectable, or Metastatic NSCLC With PD-L1 Expression of 50% or MoreWed,